

Investigating Machine Learning Methods for Survival Prediction with an Application to TCGA Breast Cancer Data

Ziyu Wang
Supervisor: Dr. Y. Gu, Department of Statistics & Actuarial Science



Introduction

Motivation:^{2,3}

1st

4th

0-54%

Most Prevalent Cancer in Women (2.3M New Cases)

Leading Cause of Cancer Mortality (666K Deaths)


Rates of Overdiagnosis

Objectives:

To compare ML models for predicting survival in breast cancer cases


To explore adjusting therapeutic interventions based on survival predictions

Pipeline



Data & Methods

Breast invasive carcinoma data sourced from TCGA (The Cancer Genome Atlas)



1. Deep Survival Analysis (DeepSurv)

Log Partial Likelihood⁵:

$$l(\theta) = -\frac{1}{N_{E=1}} \sum_{i:E_i=1} (\hat{h}_\theta(x_i) - \log \sum_{j \in \mathcal{R}(T_i)} e^{\hat{h}_\theta(x_j)}) + \lambda \|\theta\|_2^2$$

of patients with event occurred

log-risk function

risk score r(x)

l_2 regularization parameter

Input Layers

Hidden Layers

linear Combination

$\hat{h}_\theta(x)$

2. Survival Support Vector Regression (Survival SVR)

Objective function⁶:

$$f(w, b) = \frac{1}{2} w^T w + \frac{\gamma}{2} \sum_{i=0}^n (\zeta_{w,b}(y_i, x_i, \delta_i))^2$$

$$\zeta_{w,b}(y_i, x_i, \delta_i) = \begin{cases} \max(0, y_i - (w^T x_i + b)) & \text{if } \delta_i = 0, \\ y_i - (w^T x_i + b) & \text{if } \delta_i = 1, \end{cases}$$

regulation parameter

Survival time S(t|x)

Support Vectors

Margin

Hyperplane

x

3. Random Survival Forest (RSF) ⁴

Bootstrap B samples, each excluding 37% as out-of-bag (OOB) data.

Grow survival trees to the full size:

Randomly select p variables at each node.

Perform log-rank splits.

Constraint:

Terminal nodes must have at least d₀ unique deaths

Predict terminal node CHF values.

Average cumulative hazard function (CHF) from all trees.

Evaluate prediction error using OOB data.

Evaluation & Results

Train-Test Split (at 4 to 1 rate)

Hyperparameter Tuning (5 repeats of 5-fold cross-validation)

Repeated Evaluation (20 times)

Evaluation Metrics:

Concordance index (C-index):

Measures the ability to rank individuals by survival times correctly.

Higher values (closer to 1) indicate better predictive performance⁷.

$$C\text{-index} = \frac{\sum_{i,j} I(T_j < T_i) \cdot I(r_j > r_i) \cdot \delta_j}{\sum_{i,j} I(T_j < T_i) \cdot \delta_j}$$


Integrated Brier Score (IBS):

Reflects overall model accuracy and calibration.

Lower values (closer to 0) signify better performance⁷.

$$IBS(\tau) = \frac{1}{\tau} \int_0^\tau \frac{1}{n} \sum_{i=1}^n \left(\frac{(0 - \hat{S}(t|x_i))^2 \cdot I(Y_i \leq t, \delta_i = 1)}{\hat{G}(Y_i)} + \frac{(1 - \hat{S}(t|x_i))^2 \cdot I(Y_i > t)}{\hat{G}(t)} \right) dt$$

Models\Metrics	C-index (95% C.I.)	IBS (95% C.I.)
CPH (as baseline)	0.261 (0.261, 0.261)	0.336 (0.336, 0.336)
DeepSurv	0.831 (0.826, 0.837)	0.122 (0.118, 0.126)
Survival SVM	0.611 (0.611, 0.611)	NA
RSF	0.450 (0.447, 0.454)	0.213 (0.212, 0.214)



Conclusion & Discussion

Clinical Insights:

Low-risk Group: employ watchful waiting or less aggressive treatments.

High-risk Group: optimize treatment plans and ensure timely interventions.

Overall Implications:

All ML models outperformed the baseline model, CPH

DeepSurv demonstrated superior predictive performance

Future Directions:

Alternative dimension reduction methods ¹

Unique challenges of subtypes like TNBC

Additional Multi-omics data for refined predictive models

References and Acknowledgement

1. Bartenhagen, C., Klein, H.-U., Ruckert, C., Jiang, X., & Dugas, M. (2010). Comparative study of unsupervised dimension reduction techniques for the visualization of microarray gene expression data. BMC Bioinformatics, 11(1). <https://doi.org/10.1186/1471-2105-11-567>

2. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. <https://doi.org/10.3322/caac.21834>

3. Dunn, B. K., Woloshin, S., Xie, H., & Kramer, B. S. (2022). Cancer overdiagnosis: A challenge in the era of screening. Journal of the National Cancer Center, 2(4), 235–242. <https://doi.org/10.1016/j.jncc.2022.08.005>

4. Ishwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008). Random survival forests. The Annals of Applied Statistics, 2(3), 841–860. <https://doi.org/10.1214/08-aos169>

5. Katzman, J., Shaham, U., Bates, J., Cloninger, A., Jiang, T., & Kluger, Y. (2016). DeepSurv: Personalized treatment recommender system using A Cox proportional hazards deep neural network. <https://doi.org/10.48550/ARXIV.1606.00931>

6. Pölsterl, S., Navab, N., & Katouzian, A. (2015). Fast training of support vector machines for survival analysis. In Machine Learning and Knowledge Discovery in Databases (pp. 243–259). Springer International Publishing.

7. Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerdts, T., Gonen, M., Obuchowski, N., Pencina, M. J., & Kattan, M. W. (2010). Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology (Cambridge, Mass.), 21(1), 128–138. <https://doi.org/10.1097/ede.0b013e3181c30fb2>

I want to express my sincere gratitude to Dr. Y. Gu, my supervisor, for her invaluable guidance and unwavering support throughout this endeavor. I also appreciate the researchers and contributors involved in the TCGA breast cancer dataset for their efforts in generating and sharing this valuable data, which formed the foundation of my research.